Literature DB >> 35615488

Combination Therapy of Chloramphenicol and Daptomycin for the Treatment of Infective Endocarditis Secondary to Multidrug Resistant Enterococcus faecium.

Sunish Shah1,2, Dayna McManus1, Jeffrey E Topal1,3.   

Abstract

A 38-years-old female with an aortic valve replacement presented to an outside hospital (OSH) with fevers and malaise. Blood cultures revealed VRE which was resistant to linezolid, resistant to ampicillin, non-susceptible to daptomycin (MIC of 8 mcg/mL), and exhibited susceptibility to gentamicin. The patient was therefore initiated on intravenous (IV) daptomycin 6 mg/kg q24h and gentamicin IV 1 mg/kg q8h. However, after 14 days of therapy with daptomycin and gentamicin, the patient was transferred to our institution for the management of cardiogenic shock and hypoxemic respiratory failure. Given the concern for treatment failure, her antimicrobial regimen was changed to IV chloramphenicol 12.5 mg/kg every 6 hours with IV daptomycin 10 mg/kg every 48 hours given an estimated creatinine clearance of 30 mL/minutes. In vitro susceptibilities for chloramphenicol were performed which confirmed susceptibility. A transesophageal echocardiogram revealed a possible abscess at the left coronary cusp and aortic valve dehiscence. The patient underwent aortic valve replacement with aortic root reconstruction. The aortic valve culture grew VRE susceptible to linezolid but resistant to ampicillin and doxycycline. The patient was deemed clinically cured after 42 days of combination therapy with daptomycin and chloramphenicol. After 6 years of follow-up, the patient has not had a recurrent VRE infection. To our knowledge, this is the first case of endocarditis secondary to VRE that was successfully managed with the combination of daptomycin and chloramphenicol.
© The Author(s) 2021.

Entities:  

Keywords:  VRE; chloramphenicol; endocarditis

Year:  2021        PMID: 35615488      PMCID: PMC9125124          DOI: 10.1177/00185787211032364

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  24 in total

1.  Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline.

Authors:  Amar Safdar; Charles S Bryan; Shawn Stinson; Donald E Saunders
Journal:  Clin Infect Dis       Date:  2002-05-09       Impact factor: 9.079

2.  BONE-MARROW HYPOPLASIA FOLLOWING USE OF CHLORAMPHENICOL EYE DROPS.

Authors:  R L ROSENTHAL; A BLACKMAN
Journal:  JAMA       Date:  1965-01-11       Impact factor: 56.272

3.  Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin.

Authors:  Ian Jenkins
Journal:  J Hosp Med       Date:  2007-09       Impact factor: 2.960

4.  Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.

Authors:  Nicholas S Britt; Emily M Potter; Nimish Patel; Molly E Steed
Journal:  Clin Infect Dis       Date:  2017-03-01       Impact factor: 9.079

5.  Thrombocytopenia with Tedizolid and Linezolid.

Authors:  Erica Yookyung Lee; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

6.  Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

7.  Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia.

Authors:  J C Ricaurte; H W Boucher; G S Turett; R C Moellering; V J Labombardi; J W Kislak
Journal:  Clin Microbiol Infect       Date:  2001-01       Impact factor: 8.067

8.  Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin.

Authors:  Robert L Thompson; Bruce Lavin; George H Talbot
Journal:  South Med J       Date:  2003-08       Impact factor: 0.954

9.  Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections.

Authors:  A H Norris; J P Reilly; P H Edelstein; P J Brennan; M G Schuster
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

10.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.